產品
Roche's Vabysmo shows sustained two-year results in difficult-to-treat nAMD
Roche reported that Vabysmo demonstrated sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration. This is follow-up data on an already-approved product, so it is graded as incremental.
大盤 開啟原文 ↗